The CD95 (APO-1/Fas) and the TRAIL (APO-2L) Apoptosis Systems
Top Cited Papers
- 1 April 2000
- journal article
- review article
- Published by Elsevier in Experimental Cell Research
- Vol. 256 (1), 58-66
- https://doi.org/10.1006/excr.2000.4840
Abstract
No abstract availableThis publication has 94 references indexed in Scilit:
- Safety and antitumor activity of recombinant soluble Apo2 ligandJournal of Clinical Investigation, 1999
- Monocyte-mediated Tumoricidal Activity via the Tumor Necrosis Factor–related Cytokine, TRAILThe Journal of Experimental Medicine, 1999
- Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cellsEuropean Journal of Immunology, 1998
- Cleavage of FLICE (caspase‐8) by granzyme B during cytotoxic T lymphocyte‐induced apoptosisEuropean Journal of Immunology, 1997
- Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover.The Journal of cell biology, 1996
- The Role of APO‐1‐Mediated Apoptosis in the Immune SystemImmunological Reviews, 1994
- Inhibition of Apoptosis in T Cells Expressing Human T Cell Leukemia Virus Type I TaxAIDS Research and Human Retroviruses, 1994
- Protection from Fas-Mediated Apoptosis by a Soluble Form of the Fas MoleculeScience, 1994
- Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor familyCell, 1993
- The human APO-1 (APT) antigen maps to 10q23, a region that is syntenic with mouse chromosome 19Genomics, 1992